ID

37603

Description

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies; ODM derived from: https://clinicaltrials.gov/show/NCT02090543

Link

https://clinicaltrials.gov/show/NCT02090543

Keywords

  1. 8/10/19 8/10/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

August 10, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Atrial Fibrillation NCT02090543

Eligibility Atrial Fibrillation NCT02090543

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
a.general criteria (group 1and group2):
Description

Criteria General

Data type

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C0205246
diagnosed non-valvular af
Description

Atrial Fibrillation

Data type

boolean

Alias
UMLS CUI [1]
C0004238
older than 18 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
general capability and willingness to perform a structured patient interview in german
Description

Patient interview German language

Data type

boolean

Alias
UMLS CUI [1,1]
C0683518
UMLS CUI [1,2]
C0017477
no participation in any other clinical or observational study over the last 3 month
Description

Participation Absent Clinical Trial Other | Participation Absent Observational Study Other

Data type

boolean

Alias
UMLS CUI [1,1]
C0679823
UMLS CUI [1,2]
C0332197
UMLS CUI [1,3]
C0008976
UMLS CUI [1,4]
C0205394
UMLS CUI [2,1]
C0679823
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C1518527
UMLS CUI [2,4]
C0205394
additional criteria for group1 (vka-experienced):
Description

Criteria Additional | Group Number

Data type

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1524062
UMLS CUI [2,1]
C0441833
UMLS CUI [2,2]
C0237753
active vka-therapy for at least 3 month without significant interruptions
Description

Vitamin K antagonists

Data type

boolean

Alias
UMLS CUI [1]
C3653316
in case of perioperative interruption vka treatment should not have been hold for more than two weeks.
Description

Interruption perioperative | Vitamin K antagonists To be stopped

Data type

boolean

Alias
UMLS CUI [1,1]
C1512900
UMLS CUI [1,2]
C1518988
UMLS CUI [2,1]
C3653316
UMLS CUI [2,2]
C1272691
additional criteria for group2 (rivaroxaban-experienced patients):
Description

Criteria Additional | Group Number

Data type

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1524062
UMLS CUI [2,1]
C0441833
UMLS CUI [2,2]
C0237753
active rivaroxaban-therapy for at least 3 month without significant interruptions
Description

rivaroxaban

Data type

boolean

Alias
UMLS CUI [1]
C1739768
in case of perioperative interruption vka treatment should not have been hold for more than two weeks.
Description

Interruption perioperative | Vitamin K antagonists To be stopped

Data type

boolean

Alias
UMLS CUI [1,1]
C1512900
UMLS CUI [1,2]
C1518988
UMLS CUI [2,1]
C3653316
UMLS CUI [2,2]
C1272691
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
participation in any other clinical or observational study over the last 3 month
Description

Study Subject Participation Status | Clinical Trial | Observational Study

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0008976
UMLS CUI [3]
C1518527

Similar models

Eligibility Atrial Fibrillation NCT02090543

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Criteria General
Item
a.general criteria (group 1and group2):
boolean
C0243161 (UMLS CUI [1,1])
C0205246 (UMLS CUI [1,2])
Atrial Fibrillation
Item
diagnosed non-valvular af
boolean
C0004238 (UMLS CUI [1])
Age
Item
older than 18 years
boolean
C0001779 (UMLS CUI [1])
Patient interview German language
Item
general capability and willingness to perform a structured patient interview in german
boolean
C0683518 (UMLS CUI [1,1])
C0017477 (UMLS CUI [1,2])
Participation Absent Clinical Trial Other | Participation Absent Observational Study Other
Item
no participation in any other clinical or observational study over the last 3 month
boolean
C0679823 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,4])
C0679823 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C1518527 (UMLS CUI [2,3])
C0205394 (UMLS CUI [2,4])
Criteria Additional | Group Number
Item
additional criteria for group1 (vka-experienced):
boolean
C0243161 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0441833 (UMLS CUI [2,1])
C0237753 (UMLS CUI [2,2])
Vitamin K antagonists
Item
active vka-therapy for at least 3 month without significant interruptions
boolean
C3653316 (UMLS CUI [1])
Interruption perioperative | Vitamin K antagonists To be stopped
Item
in case of perioperative interruption vka treatment should not have been hold for more than two weeks.
boolean
C1512900 (UMLS CUI [1,1])
C1518988 (UMLS CUI [1,2])
C3653316 (UMLS CUI [2,1])
C1272691 (UMLS CUI [2,2])
Criteria Additional | Group Number
Item
additional criteria for group2 (rivaroxaban-experienced patients):
boolean
C0243161 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0441833 (UMLS CUI [2,1])
C0237753 (UMLS CUI [2,2])
rivaroxaban
Item
active rivaroxaban-therapy for at least 3 month without significant interruptions
boolean
C1739768 (UMLS CUI [1])
Interruption perioperative | Vitamin K antagonists To be stopped
Item
in case of perioperative interruption vka treatment should not have been hold for more than two weeks.
boolean
C1512900 (UMLS CUI [1,1])
C1518988 (UMLS CUI [1,2])
C3653316 (UMLS CUI [2,1])
C1272691 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Study Subject Participation Status | Clinical Trial | Observational Study
Item
participation in any other clinical or observational study over the last 3 month
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2])
C1518527 (UMLS CUI [3])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial